SUMMARY: Immune response of man to various Habu-venom toxoids with different potencies was investigated. A linear relationship was observed between circulating anti-HR1 and the amount of HR1 toxoid used for the basic immuniza tion. A highly purified toxoid was 2.5 times more effective in man than partially purified ones, when compared on the basis of the immunizing unit determined in guinea pigs. Out of 265 vaccinees, 202 (76.2%) produced anti-HR1 exceeding 1 U/ml after two injections of the mixed toxoid and the rate rose to 96% after the booster immunization, when the preparation contained HRl toxoid of not less than 9ImU per dose. The rate fell to 58% and 28.5%, 12 months and 24 months after the last injection, respectively. Although booster immunization was effective to restore the declined antibody production, the level of anti-HRl after the injection did not exceed that after the basic immunization in the groups primed with partially purified HR 1 toxoid. Neither increased number of injection nor changed duration of intervals of successive injections for the basic immunization improved the immune response of man. Booster effect was slightly higher in the groups primed with a highly purified toxoid, but its magnitude was much smaller than that in the case of other kinds of toxoid (e.g., tetanus toxoid).
INTRODUCTION
Although the administration of antivenom is the most effective cure for envenomation from bite by Habu snake (Trimeresurus flavoviridis), delayed treatment results in severe residual symptoms (Sawai et al., 1962) . Active immunization is urgently required by people on the remote islands. The venom is known to contain two hemorrhagic principles (HR1 and HR2) and a lethal toxin which is associated with HR1 preparations (Ohsaka et al., 1960; Kondo et al., 1965a,b; Omori-Satoh and Ohsaka, 1970) . Kondo, S. et al., (1971) showed 197 2) Prepared by the method described by Sawai et al. (1972) . See the text. 3) Amount of HR2 toxoid was reduced by accident. 4) Total protein. (Kondo, H. et al., 1971b) . Although the toxoid was immunogenic to man (Someya et al., 1972) , production of anti-HR1 was rather poor in human beings and monkeys as compared with other animals (Kondo, H. et al., 1971b) . Sadahiro et al. (1978) Txd 15, while the figure was 5.9 with Txd 36 prepared from toxins of high purity. As a result, the anti-HR1 titers after the booster injections were not significantly higher than those after the basic immunization in the groups receiving the preparation derived from Step 1 toxin. The difference in immune response by age was not significant as will be seen from 49A and 49S (see legend (1) to Table II) .
Effect of the Method of Immunization on Antitoxin Production
In some experiments, three successive injections were given for the basic immunization. As shown in Table III , no definite evidence was observed to prove that three injections were more effective for anti-HR1 production in man than two injections. Nor did the number of injection affect antitoxin production after booster injection.
In some experiments, the first and second injections were carried out at a week's interval to see whether larger doses at the beginning would be beneficial. However, as shown in Table IV , no consistent difference was observed depending on the method of immunization, although some differences were occasionally observed. Table V shows the changes in titers of anti-HR1 and anti-HR2 after successive injections for the basic immunization. The data were taken from the experiments shown in Tables II to IV. The rise in antitoxin titer was evident after the second injection, but the effect of the third injection was not consistent with respect to anti-HR1 or anti-HR2 response.
Dose Response Relationships in Anti-HR1 Production
Anti-HR1 titers were plotted against the amount of HRl toxoid in ImU used for basic immunization as shown in Fig. 1 . The figure was constructed from the data given in Tables II, III and IV. In such groups where the third injection was not effective, the results after the second injection were used (refer to Table V) . The results of the groups immunized with the same toxoid were combined. Statistical analysis showed no heterogeneity in variance nor significant difference in the mean antitoxin titers. An exceptional value of group 45B was omitted from the calculation, which will be discussed later. Statistical analysis did not reject the assumption that dose-response regression is linear for all groups except 45B (not shown in the figure) . However, the linearity may fit better when the results were divided into two groups depending on the purity of the toxoid as shown in Fig. 1 .
Effect of Repeated Immunization on Anti-HRI Production
In a previous paper, Sadahiro et al. (1978) reported the fate of anti-HR1 over several years in the group immunized with Txd 12. Since this preparation TABLE III Effect of number of injection for the basic immunization 1) Volunteers received 3 or 2 injections of 0.5 ml at the intervals shown in the parentheses.
Groups with 2 injections were the same ones appeared in Table II . w: week; m: month 2) 1st Bleeding (1): 4-6 weeks after the last injection of the basic immunization.
2nd Bleeding (2): 11-12 months after the basic injection. 3) A single injection of 0.5 ml of each toxoid was given to each volunteer.
3rd Bleeding (3): 4 weeks after the injection, except for 48-A and 48-C (10 weeks). 4th Bleeding (4): 6 months for 53-A and B: 14 months for 47-A and B ; 24-25 months for 48-A and 48-C. 4) * Difference between 48-A and 48-C was significant at P=0.05. Others : refer to the legends to Table II. TABLE IV Effect of the interval of injection for the basic immunization 1) Volunteers received 3 or 2 injections of 0.5 ml at the intervals shown in the parentheses.
w: week; m: month 2) 1st Bleeding (1): 4 weeks for 48-A and 48-B and 14 weeks for 50-A and 50-B after the 3rd injection. 2nd Bleeding (2): 10-11 months after the 3rd injection.
3) A single injection of 0.5 ml of each toxoid was given to each volunteer.
3rd Bleeding (3): 4 weeks for 50-A and B and 10 weeks for 48-A and 48-B after the injection. 4th Bleeding (4): 24-25 months after the injection. 4)* Differences between two groups were significant at P=0.05. Others: refer to the legends to figure. After the second booster injection, other preparations of toxoid than those used for the basic immunization were used. After the fourth booster, the amount of toxoid was reduced to 0.2 ml. As shown in Fig. 2 , the effects of repeated booster injections were not so conspicuous, contrary to the exception from the experiences with other kinds of toxoid (e.g., tetanus toxoid, Someya et al., 1978a,b) . The anti-HR1 titers remained on the same level after the basic (Txd 12 and Txd 13) or after the first booster (Txd 15) injection. Furthermore, decrease in antitoxin titer after the booster injection was observed in some individuals, especially in those with high titer before the booster injection (unpublished data). Such a phenomenon was not related to the number of injection nor to the kind of toxoid preparation.
Antitoxin Production in Man with Habu Toxoid
Several thousands of volunteers on Amami Islands each received two or three injections of one of the toxoid preparations with different potencies, followed by a booster injection after several months. Some vaccinees received repeated booster injections. Several hundreds of serum specimens taken at various immunization periods were titrated semiquantitatively for the contents of anti-HR1 and anti-HR2. The results are summarized in Table VI . About 60% of the vaccinees showed anti-HR1 of higher than 1 U/ml. If only the toxoids of 18 ImU/ml or higher were taken into consideration, the figure would be 76% and 96%, after the basic and booster injections, respectively. However, the figures fell to about 50% of the vaccinees 10-12 months after immuni-zation, and to 30% 2 years after the booster injection. Anti-HR2 seemed to persist longer than did anti-HR1 when 1 U/ml was taken as the criterion.
Side Reactions
Besides the vaccinees who were examined for circulating antitoxin as mentioned above, many other volunteers were immunized with Habu toxoid during the period of 1970-1979, the total number being 8,206. Side reactions were examined by one of the authors (H.F.). The reactions were in most cases local swelling and redness. As a general reaction , urticaria developed in 10 among 23,336 doses. Four persons had history of the symptom to other agents . Table VII summarizes the local reactions. As will be seen , toxoids with high aluminum contents (Txd's 12, APF, 15, 18) developed more cases of swelling at the first injection than did those of low aluminum contents (Txd's 13 , 14, 36) . The larger the number of injections, the higher the frequency of side reaction in most cases. Appearance of severe reactions was rather incidental; it was not related to the kind of the toxoid preparations but was observed after two or more injections. In some occasions (Txd 13-4th, Txd 14-3rd, Txd 15-4th injections), the incidence of side reactions seemed to decrease after repeated injections (see below). Table II and Fig. 1 suggest that a linear relationship may exist between the dosage of HR1 toxoid and anti-HR1 response after the basic immunization, although we must be cautious to draw a conclusion from the experiments carried out at different times. The lineality may fit better when the toxoids were grouped depending on their purity. The position of dose-response line for a highly purified toxoid (Txd 36) seems to be different from that of partially purified toxoids. The relative efficacy was 0.4118 with fiducial limits (P=0.95) of 0.099 and 1.0017, when calculated on the basis of the amount of HR1 toxoid (ImU) used for the basic immunization; that is, the highly purified toxoid was 2.58 times more effective than the partially purified toxoids. Such a high level of anti-HR 1 that had never been attained with partially purified toxoids was. observed with Txd 36 after not only the basic but also the booster injection (Table II) . The magnitude of the slope (0.42) of the dose-response line suggests that 10 times higher antigenicity may be required to increase the level of anti-HR1 by 2.5 times. However, the amount of total protein should be limited for the preparation for human use. To increase the immunogenicity, use of highly purified toxoid together with adequate adjuvants is necessary.
DISCUSSION
Table II suggests also that the rate of decline in antitoxin titer was not parallel to the values attained immediately after the basic immunization. The higher titers found after one year in the groups immunized with Txd 12 and Txd 15 may be related to the high aluminum contents, as shown in the case RESPONSE  OF MAN  TO  VENOM  TOXOID   207 of diphtheria toxoid (Holt, 1950) . However, a large amount of aluminum may not be recommended, and establishment of new adj uvants is urgently wanted for (Yamamoto et al., 1979) . The method of administration may influence the immune response of man to toxoid preparations (Someya et al., 1978a,b) . However, no consistent evidence was observed to support that increased number of injection improved the human response to HR 1 toxoid derived from partially purified toxoid (Table III) . The antitoxin titer reached the maximum after the second injection (Table V) . In a few vaccinees, the third injection resulted in reduction of the antitoxin titer. With Txd 36, however, three injections may be promising not only for the basic but also for the booster immunization, although not statistically significant (Table II) . Further experiments are needed on this point.
The interval of the injections for basic immunization may influence the immune response of man. Thus, Someya et al. (1981) showed that an interval of 6 weeks between the first and the second injection was preferable to that of 4 or 8 weeks in the case of diphtheria toxoid. However, no consistent results were obtained in the case of Habu toxoid, as illustrated in Table IV .
The booster effect of HR1-toxoid was not conspicuous when compared with diphtheria or tetanus toxoid (Someya et al., 1978a,b) . The ratio of anti-HR1 after/before booster injection (A/B ratio) was about 2 and 6.0, for the partially and highly purified toxoids, respectively. However, A/B ratios of tetanus and diphtheria toxoids were more than 30 (over 100 in many occasions). Repeated immunization with the partially purified toxoid did not improve the level of anti-HR1 nor of anti-HR2. However, the anti-HR1 titers observed in these groups (2-5 U/ml) may not be the maximum values in man, since titers higher than 10 U / ml (maximum 45 U / ml) were observed among those primed with a highly purified toxoid. It is not possible at present to explain whether the poor booster effect is due to the nature of toxic principles or due to some other f actor(s) contaminating the preparation of Habu toxoid. This problem should be further investigated by comparing the immunogenicity of HR1 toxoids of different purities (Sadahiro et al., 1981 b) . It is also of interest to study the avidity of the antitoxin. However, the present technique of toxin neutralization may not be suitable for such studies because of its low sensitivity.
Some comments may be necessary about the peculiar response of group 45B
given two injections of 0.1 ml for the basic immunization. The antitoxin titers were not different from those of 45A group receiving 0.5 ml. This was also the case with APF toxoid (Someya et al., 1972) . Although no evidence was available to explain such a phenomenon, some factors may be considered:
(1) Slope of dose-response line may be much smaller when volume of the inoculum changed. We found that such was actually the case in guinea pigs (unpublished data). (2) The slope may be smaller as the amount of adjuvant increases. (3) Both factors may be additive. In addition, large variation in human response should be considered as in the case of diphtheria toxoid (Someya et al., 1978a) . In such occasions, the number and homogeneity of the vaccinees RESPONSE  OF MAN  TO  VENOM  TOXOID  209 may greatly influence the results. It is of interest to scrutinize the immunological characteristics of low and high responders. The Committee on Habu Toxoid suggested that circulating antitoxins of more than 1 unit/ml may be useful to alleviate symptoms of envenomation caused by the bite by Habu snake (Someya et al., 1972) . Table VI shows that about 60% of vaccinees who have completed the basic immunization with 0.5 ml of Habu toxoid produced anti-HR1 exceeding 1 U/ml and the rate rose to 78% if only the toxoids with a potency of 18ImU/ml or more were considered. After booster injection, 96% of the vaccinees showed anti-HR1 exceeding the level. However, the rate decreased to 50% 10-12 months and to 20-30% 2 years after the last injection. The poor immune response of 13B after the basic immunization cannot be explained now. Such a difference in the response was not rare in the field trials with other toxoids (Someya et al ., 1978a) . These results show that at least 20ImU/m1 should be used to immunize human beings; a preparation of more than 50ImU/m1 may be desirable . The present experiment also suggests that several booster injections may be necessary for the person at risk. For this purpose, use of highly purified toxoid is preferable. Furthermore, adequate adjuvants for human use are urgently required to improve the immune response of human beings to Habu toxoid. A more sensitive and simple method for antitoxin titration should be developed to solve many problems left for the future study. Studies on this point are going on now.
With regard to the side reactions (Table VII) , no systemic reaction was observed. Urticaria was observed in a few vaccinees, but most of them had history of the disease against other agents. The main reaction was local irritation. The frequency was dependent mainly on the aluminum contents , as shown in Table VII . The frequency increased when immunization was repeated . The apparent decrease after repeated injections was probably due to the fact that those who showed some reactions by the preceding injection did not receive further injection. The reactions to Txd 36 were less severe compared to those to other preparations.
